Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
Part of paid clinical trials in Duarte, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT07235501
- Status
- Recruiting
Conditions
- Graft Versus Host Disease
- Hematopoietic and Lymphatic System Neoplasm
- Malignant Solid Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 7 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Non-Interventional Study — OTHERNon-interventional study
Study Details
This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.
Key Dates
- First listed
- Nov 19, 2025
- Start date
- Oct 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Jan 17, 2030
- Completion
- Jan 17, 2030
Study Design
- Enrollment
- 75 participants (estimated)
Arms
- Arm: Observational Cohort 1Patients undergo blood, saliva/buccal, and stool sample collection for up to 2 years on study. Patients also have their medical records reviewed on study.
- Arm: Observational Cohort 2Patients undergo a one-time blood, saliva/buccal, and stool sample collection and have their medical records reviewed on study.
Primary Outcome Measure
T cell measurements [ Time Frame: Up to 2 years - study completion ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Ryotaro Nakamura (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
By research site
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- Collection and Storage of Tissue and Blood Samples From Patients With CancerRecruiting · National Cancer Institute LAO · Fort Smith, Arkansas
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Sacramento, California
- Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid TumorsRecruiting · SWOG Cancer Research Network · Anchorage, Alaska